The influence of combined treatment of interleukin-2 and chemotherapy on T lymphocyte subgroup in acute myeloid leukemia

VernacularTitle:白细胞介素-2联合化疗对急性髓系白血病T淋巴细胞亚群影响的研究
Author: Xiaolian LIU ; Wanshou ZHU ; Zhi LIU ; Shijian HUANG ; Shenghua LI
Publication Type:Journal Article
Keywords: Leukemia,myeloid; Interleukin-2; T-lymphocyte subsets; Drug therapy,combination
From: Chinese Journal of Postgraduates of Medicine 2011;34(19):32-33
CountryChina
Language:Chinese
Abstract: Objective To investigate the influence and the clinical significance of interleukin-2 (IL-2) on T lymphocyte subgroup after chemotherapy in acute myeloid leukemia patients. Methods Fiftyfour acute myeloid leukemia patients were divided into treatment group (chemotherapy combined with IL-2,28 cases) and control group (pure chemotherapy,26 cases) by radom digits table. In treatment group, IL-2400 000 U was dripped after chemotherapy for 14 days. Then the T lymphocyte subgroup change before and after treatment was examined. Results After 14 days' treatment, the levels of CD3 (0.6026±0.2275 ),CD4(0.4972±0.1224),CD56(0.3016±0.1053 ) in treatment group were significantly higher than those before treatment(0.3926±0.2010,0.2264±0.1190,0.1729±0.1226) and in control group (0.4352±0.1930,0.2738±0.1362,0.1937±0.1268)(P< 0.05). Conclusion IL-2 treatment can obviously raise the levels of T lymphocyte subgroup and can raise the immunologic function.